Anna Unseld
- 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthmaBy Eckard Hamelmann, Attilio Boner, Jonathan Bernstein, Petra Moroni-Zentgraf, Michael Engel, Mandy Avis, Anna Unseld and Mark VandewalkerEckard Hamelmann2Department of Child and Adolescent Medicine, St. Josef Hospital, Bochum, GermanyAttilio Boner1Pediatric Department, University of Verona, Verona, ItalyJonathan Bernstein3Department of Internal Medicine, University of Cincinnati Medical Sciences Building, Cincinnati, OH,Petra Moroni-Zentgraf4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyMichael Engel4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, GermanyMandy Avis5Trial Clinical Monitor, Boehringer Ingelheim bv, Alkmaar, NetherlandsAnna Unseld6Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyMark Vandewalker7Medical Director, Clinical Research of the Ozarks, Columbia, MO,
- Once-daily tiotropium respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysisBy Daniel Dusser, Roland Buhl, Mario Castro, Huib Kerstjens, Pierluigi Paggiaro, Michael Engel, Petra Moroni-Zentgraf, Anna Unseld and Eric BatemanDaniel Dusser1Pulmonary Department and Adult Cystic Fibrosis Center, Université Paris Descartes, Sorbonne Paris Cité, Cochin Hospital, Paris, FranceRoland Buhl2Pulmonary Department, Mainz University Hospital, Mainz, GermanyMario Castro3Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO,Huib Kerstjens4Department of Pulmonary Medicine and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, NetherlandsPierluigi Paggiaro5Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, ItalyMichael Engel6TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co., Ingelheim am Rhein, GermanyPetra Moroni-Zentgraf6TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co., Ingelheim am Rhein, GermanyAnna Unseld7Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, GermanyEric Bateman8Department of Medicine, University of Cape Town, Cape Town, South Africa
- The antitussive pentoxyverine (POV) does not affect the electrocardiogram (ECG), and in particular not the corrected QT (QTc) interval: Results from a phase I clinical trialBy Ulrich Feifel, Michael Könen-Bergmann, Anna Unseld and Thomas WeiserUlrich Feifel1Transl. Medicine & Clin. Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyMichael Könen-Bergmann2TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, GermanyAnna Unseld3Global Biometry & Clin. Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, GermanyThomas Weiser4Medical Affairs Germany, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.